We're pleased to announce the initiation of dosing in our first-in-human Phase 1 clinical trial of CEL383 in healthy volunteers. CEL383 is a potential first-in-class anti-TREM1 antibody that Celsius is advancing for the treatment of #IBD. Read more: https://t.co/02qBb8Vx9u
We're officially in the second half of 2023. We're excited to celebrate eight mid-year promotions! Each of these team members have demonstrated the curiosity and relentless attitude required to move our medicines closer to patients in need. Congratulations!
Celsius recently turned 5 years old, which calls for celebration! We got together to enjoy a toast, trivia and a little walk down memory lane as we reflected on how we've grown. We came away with a sense of excitement for all that's to come for our incredible team. Cheers!
Yesterday, Celsius CEO @tkassum spoke on a panel at #WMIF2023 discussing the potential benefits of new mechanisms and precision approaches for inflammatory diseases. Thank you, @MGBInnovation, for hosting this week's event!
Our CBO, Mike Boretti, and Associate Director of Business Development & Strategic Alliances, Malcolm Daniels, enjoyed a productive week of great conversation at #BIO2023 this week. Big thanks to @IAmBiotech for another successful meeting!
Despite the gloomy weather in Boston, we had a great day Taking Steps towards a cure w/ the @CrohnsColitisFn on Saturday. We're proud to support their incredible efforts as we work to create new treatment options for people living with diseases like Crohn's & ulcerative colitis.
Team Celsius is gearing up for the @CrohnsColitisFn#TakeSteps walk this weekend in Boston! Learn how you can support our team and CCF: https://t.co/cVDp1FsXh5
For #WorldIBDDay, we were thrilled to welcome @CrohnsColitisFn Honoree Matt Cohen to Celsius. Hearing patient stories like his reminds us how important our work is. We will be walking alongside honorees like Matt at this year's #TakeSteps Boston walk. https://t.co/cVDp1FsXh5
Team member Bryan Erwin says the culture and positive work environment stood out to him throughout his interview process, ultimately leading him to join the team. Learn more about one of our newest hires in this month's employee spotlight!
It’s estimated that ten million people worldwide live with #IBD. Celsius is honored to join the fight against ulcerative colitis and Crohn’s disease. CMO Sarah Grant shares more in honor of #WorldIBDDay2023.
It's our 5th birthday! There have been many moments of growth, excitement & perseverance over the past 5 years. Thanks to the dedication of our team, past & present, we look forward to continuing our advancement of precision medicine in inflammatory disease in the years to come.
We're thrilled to share a prepublication of results from our collaboration with the @UniofOxford. We look forward to sharing more about this productive partnership in the coming weeks.
Longitudinal scRNAseq in biologic naive patients with IBD - adalimumab:
https://t.co/ULbAUUFERk
This work was made possible by patients and clinical colleagues at the TGU(Oxford), QEHB(Bham), colleagues @KirOxford,@HumanGeneticsOx ,@celsiustx who helped deliver despite COVID
We're excited to share Celsius has been awarded a Workforce Training Fund grant through @CommCorp_MA. This has been an incredible professional development opportunity for our team. Thank you to our partners at Hands On for their help in obtaining the grant & leading our programs.
This semester, we've been lucky to have four incredible co-ops from @Northeastern, @Wellesley and @EPFL_en at Celsius. Their mentors have loved having them as a part of our team. We look forward to watching them continue to grow and contribute as we move our efforts forward.
We're identifying and validating multiple targets in colorectal cancer through our collaboration with @ServierPharma. Today is #DressInBlueDay for #ColorectalCancer awareness month. Learn more here. https://t.co/MqDejsBzVo
In honor of #BlackHistoryMonth, last week, our team gathered for conversation and celebration with treats from two local Black-owned businesses, @CupcakeTherapy_ and @midarestaurant. Thank you for your incredible food and contributions to our community!
We're pleased to share that our chief medical officer, Sarah Grant, will be presenting new single cell data highlighting CEL383 and the identification of TREM1 as an exciting target for #IBD at #ECCO - IBD this week in Copenhagen. Read more: https://t.co/t1CRLoQrXe
Congratulations to our 2022 Annual Award winners. Their dedication to staying curious, being connected with others and pursuing our goals relentlessly has exceeded our expectations the past year. We're so grateful to have them on our team!